Chemical Enhancers for the Absorption of Substances Through the Skin: Laurocapram and Its Derivatives

REFERENCES

• Afouna M. I. Influence of various Azone concentrations upon the permeability parameters for acyclovir (ACV) and (E)-5-(2-Bromovinyl)-2-deoxyuridine (BVDU) topical formulations using hairless mice: a comparative study. Al-Azhar J. Pharm. Sci. 2001; 28: 26–38
   Google Scholar
• Afouna M. I., Fincher T. K., Zaghloul A. A., Reddy I. K. Effect of azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice. International Journal of Pharmaceutics 2003; 253: 159–168, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Agyralides G. G., Dallas P. P., Rekkas D. M. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int. J. Pharm. 2004; 281(1–2)35–43, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Akhter S. A., Barry W. J. Penetration enhancers in human skin—effect of oleic acid and Azone on flurbiprofen permeation. J. Pharm. Pharmacol. Dec. Suppl. 1984; 36: 7P, [CSA]
   PubMedGoogle Scholar
• Akimoto J., Takayama K., Isowa K., Nayai T. Evaluation of skin irritation of percutaneous absorption promoters by means of fractal dimension of rat skin structure. Int. J. Pharm. 1996; 128(1–2)251–260, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Akitoshi Y., Takayama K., Machida Y., Nagai T. Effect of cyclohexanone derivatives on percutaneous absorption of ketoprofen and indometacin. Drug. Des. Deliv. 1998; 2: 239–251, [CSA]
   Google Scholar
• Alberty W. J., Hadgraft J. Percutaneous Absorption: Theorical Description. J. Pharm. Pharmacol. 1979a; 31: 129–139, [CSA]
   PubMed Web of Science ®Google Scholar
• Alberty W. J., Hadgraft J. Percutaneous Absorption: in vivo Experiments. J. Pharm. Pharmacol. 1979b; 31: 140–147, [CSA]
   PubMed Web of Science ®Google Scholar
• Allan G. Azone®. Percutaneous Penetration Enhancers1st, E. W. Smith, H. I. Maibach. Informa UK Ltd, New York 1995; 129–136
   Google Scholar
• Bai G., Luo B. The in vitro effect of Azone on the percutaneous absorption of tinidazole (TNZ) gel. Zhongguo Kangshengsu Zazhi 1999; 24(4)302–303, [CSA]
   PubMedGoogle Scholar
• Barry B. W. Mode of action of penetration enhancers in human skin. Journal of Controlled Release 1987; 6: 85–97, [CSA], [CROSSREF]
   Google Scholar
• Beastall J. C., Hadgraft J., Washington C. Mechanism of action of Azone as a percutaneous penetration enhancer: Lipid bilayer fluidity and transition temperature effects. International Journal of Pharmaceutics 1998; 43(2)207–213, [CSA]
   Google Scholar
• Bennett S. L., Barry B. W., Woodford R. The assessment of some potential penetration enhancers using the vasoconstrictor test. J. Pharm. Pharmacol., Dec. Suppl. 1984; 36: 8P, [CSA]
   Google Scholar
• Bonina F. P., Montenegro L., De Capraris P., Bousquet E., Tirendi S. 1-Alkylazacycloalkan-2-one esters as prodrugs of indomethacin for improved delivery through human skin. Int. J. Pharm. 1991; 77(1)21–29, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Bosman I. J., Ensing K., De Zeeuw R. A. Standardization procedure for the in vitro skin permeation of anticholinergics. Int. J. Pharm. 1998; 169(1)65–73, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Budavari S., O'Neil M. J., Smith A., Heckelman P. E., Kinneary J. F. Manual Merck12. Informa UK Ltd, New Jersey 1996; 920
   Google Scholar
• Bymaster F. P., Shannon H. E., Shipley L. A., Valia K. H. Transdermal formulation of 3-[3-(hexylthio)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine having muscarinic activity. EP Patent 727209 A2, (August 21, 1996)
   Google Scholar
• Cato A., Swinehart J. M., Griffin E. I., Sutton L., Kaplan A. S. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int. J. Dermatol. 2001; 40(3)232–236, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cato Allen, Sutton Lynda, Kaplan Allan S., Manning George, N. Activity of a triamcinolone acetonide/laurocapram formulation: double-blind comparisons with triamcinolone acetonide, placebo vehicle, and mid-strength (Class IV) to potent (Class II) corticosteroids. Curr. Ther. Res. 2001; 62(3)180–186, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Degim I. T., Uslu A., Hadgraft J., Atay T., Akay C., Cevheroglu S. The effects of Azone and Capsaicin on the permeation of Naproxen through human skin. Int. J. Pharm. 1999; 179(1)21–25, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Demierre M., Vachon L., Ho V., Sutton L., Cato A., Leyland-Jones B. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch. Dermatol. 2003; 139(5)624–628, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dimas D. A., Dallas P. P., Rekkas D. M. Use of an 8(sup)1(/sup)3(sup)2(/sup) asymmetrical factorial design for the in vitro evaluation of ondansetron permeation through human epidermis. Pharmaceutical Development and Technology 2004; 9(1)39–48, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ding P., Zheng J. Skin-Penetrating Absorption Preparation. CN Patent 1154842, July 7, 1997
   Google Scholar
• Ermolina I., Smith G., Ryabov Ya., Puzenko A., Polevaya Yu., Nigmatullin R., Feldman Yu. Effect of penetration enhancers on the dynamic behavior of phosphatidylcholine headgroups in liposomes. J. Phys. Chem. B. 2000; 104(6)1373–1381, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Escobar-Chávez J. J., Quintanar-Guerrero D., Ganem-Quintanar A. In vivo skin permeation of sodium naproxen formulated in pluronic f-127 gels: Effect of Azone® and transcutol®. Drug Dev. Ind. Pharm. 2005; 31(4–5)447–454, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fang J. Y., Fang C. L., Hong Ch T., Chen H. Y., Lin T. Y., Wei H. M. Capsaicin and nonivamide as novel skin permeation enhancers for indomethacin. Eur. J. Pharm., Sci. 2001; 12(3)195–203, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fang J. Y., Hsu L. R., Huang Y. B., Tsai Y. H. Evaluation of transdermal iontophoresis of enoxacin from polymer formulations: in vitro skin permeation and in vivo microdialysis using wistar rat as an animal model. Int. J. Pharm. 1999; 180(2)137–149, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fang J. Y., Hwang T. L., Fang C. L., Chiu H. C. In Vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug. Int. J. Pharm. 2003; 255: 153–166, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fu R., He F., Li J. Effects of penetration enhancers on percutaneous absorption of ketoprofen gel. Huaxi Yaoxue Zazhi 1999; 14(5–6)323–325, [CSA]
   Google Scholar
• Fuhrman L. C., Jr., Michniak B. B., Behl C. R., Malick A. W. Effect of novel penetration enhancers on the transdermal delivery of hydrocortisone: an in vitro species comparison. J. Controll. Rel. 1997; 45: 199–206, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Ganem R. A., Piñón S. E., Quintanar G. D. Uso de Promotores de Absorción Percutánea. Ciencia Cosmética 1998; 4: 19–25, [CSA]
   Google Scholar
• Ganem-Quintanar A., Kalia Y. N., Falson-Rieg F., Buri P. Mechanism of oral permeation enhancement. Int. J. Pharm. 1997; 156: 127–142, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Ganga S., Ramarao P., Singh J. Effect of Azone on the iontophoretic transdermal delivery of metoprolol tartrate through human epidermis in vitro. J. Control. Rel. 1996; 42(1)57–64, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Gao J. Q., Liang W. Q. Synergism of Laurocapram and iontophoresis on percutaneous permeation of non-steroid anti-inflammatory drugs in vitro. Zhongguo Yiyao Gongye Zazhi 1998; 29(4)169–172, [CSA]
   Google Scholar
• Goffin V., Henry F., Piérard-Franchimont C., Piérard G. E. Penetration enhancers assessed by corneoxenometry. Skin Pharmacology and Applied Skin Physiology 2000; 13(5)280–284, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hadgraft J. Physicochemical determinants of skin penetration enhancement. 3rd Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, JerusalemIsrael, Sep, 1–6. Informa UK Ltd, JesusalemIsrael 1996; 3
   Google Scholar
• Hadgraft J., Williams D. G. Azone®. mechanisms of action and clinical effect. Pharmaceutical Skin Penetration Enhancement, K. A. Walters, J. Hadgraft. Informa UK Ltd, New York 1993; 182
   Google Scholar
• Hadgraft J., Peck J., Williams D. G., Pugh W. J., Allan G. Mechanisms of action of skin penetration enhancers/retarders: Azone and analogs. International Journal of Pharmaceutics 1996; 141(1–2)17–25, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Hadgraft J., Walters K. A., Wotton P. K. Facilitated transport of sodium salicylate across an artificial lipid membrane by Azone. J. Pharm. Pharmacol. 1985; 37: 725–727, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hirvonene J., Rajala R., Viihervaara P., Laine E., Parone P., Urtti A. Mechanism and reversibility of penetration-enhancer action in the skin. A DSC study. European Journal of Pharmaceutics and Biopharmaceutics 1994; 40(2)81–85, [CSA]
   Web of Science ®Google Scholar
• Hoogstrate A. J., Verhoef J., Brussee J., Ijzerman A. P., Spies F., Bodde H. E. Kinetics, Ultrastructural Aspects and Molecular Modeling of Transdermal Peptide Flux Enhancement by N-Alkylazacycloheptanones. Int. J. Pharm. 1991; 76(1–2)37–47, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Kanikkannan N., Slingh J., Ramarao P. Transdermal iontophoretic delivery of timolol maleate in albino rabbits. Int. J. Pharm. 2000; 197(1–2)69–76, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Katsu T., Kuroko M., Sanchika K., Morikawa T., Kurosaki Y., Nakayama T., Kimura T., Fujita Y. Interaction of 1-dodecylazacycloheptan-2-one (Azone) with erythrocyte membrane. International Journal of Pharmaceutics 1989; 53(1)61–66, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Khaled K. A., El-Sayed Y. M., Al-Bawardi I. S. Effects of formulations and penetration enhancers on the diffusional parameters for the percutaneous absorption of propranolol hydrochloride. Bulletin of Pharmaceutical Sciences 2001; 24(1)65–71, [CSA]
   Web of Science ®Google Scholar
• Kumar A., Leonard M. F., Alfano J., Murray D. L., Cleveland R. P., Beaman D. C. Therapeutic efficacy of acyclovir and acyclovir—laurocapram combination on herpes simplex in an immunocompromised baby guinea pig model. Curr. Ther. Res. 1987; 41(6)802–8, [CSA]
   Web of Science ®Google Scholar
• Kurosaki Y., Hisaichi S., Nakayama T., Kimura T. Enhancing effect of 1–dodecylazacycloheptan-2-one (Azone) on the absorption of salicylic acid from keratinized oral mucosa and the duration of enhancement in vivo. Int. J. Pharm. 1989; 51(1)47–54, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• López A., Linares F., Cortell C., Herráez M. Comparative enhancer effects of Span 20 with Tween 20 and Azone on the in vitro percutaneous penetration of compounds with different lipophilicities. Int. J. Pharm. 2000; 202(1–2)133–140, [CSA]
   PubMed Web of Science ®Google Scholar
• López-Castellano A., Cortell-Ivars C., López-Carballo G., Herráez-Domingues M. The Influence of Span20 on stratum corneum lipids in langmuir monolayers: comparison with Azone. Int. J. Pharm. 2000; 203(1–2)245–253, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lewis D., Hadgraft J. Mixed Monolayers of dipalmitoylphosphatidylcholine with Azone or oleic acid at the air-water interface. International Journal of Pharmaceutics 1990; 65(3)211–218, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Liu J., Zhou N. Studies on effects of enhancers on aminophylline transdermal therapeutic system and its mechanism. Zhongguo Yaoxue Zazhi 2001; 36(8)534–536, [CSA]
   Google Scholar
• Liu Y., Xue H., Yang W., Chen Z., Jing G., Teng D. Cutaneous absorption test of zinc gluconate cream. Zhongguo Yiyuan Yaoxue Zazhi 1999; 19(4)199–201, [CSA]
   Google Scholar
• Lu W., He L. C. Study on the transdermal permeability of coumarins in radix angelica dahurica in vitro. Chinese Pharmaceutical Journal 2003; 38(12)939–941, [CSA]
   Google Scholar
• Meidan V. M., Al-Khalili M., Michniak B. B. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int. J. Pharm. 2003; 264(1–2)73–83, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meidan V. M., Docker M. F., Walmsley A. D., Irwin W. J. Phonophoresis of hydrocortisone with enhancers: an acoustically defined model. Int. J. Pharm. 1998; 170(2)157–168, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Meidan V., Walmsley A. D., Docker M. F., Irwin W. J. Ultrasound-enhanced diffusion into coupling gel during phonophoresis of 5-fluorouracil. Int. J. Pharm. 1999; 185(2)205–213, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Michniak B. B., Player M. R., Fuhrman L. C., Christensen C. A., Chapman J. M., Jr., Horwell J. W., Sr. In vitro evaluation of a series of Azone analogs as dermal penetration enhancers. II. (Thio) amides. Int. J. Pharm. 1993b; 94(1–3)203–210, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Michniak B. B. Azone® analogues as penetration enhancers. Percutaneous Penetration Enhancers1, E. W. Smith, H. I. Maibach. Informa UK Ltd, New York 1995; 183–194
   Google Scholar
• Michniak B. B., Player M. R., Chapman J. M., Jr., Sowell J. W., Sr. In vitro Evaluation of a Series of Azone Analogs as dermal penetration enhancers. Int. J. Pharm. 1993a; 91(1)85–93, [CSA]
   Web of Science ®Google Scholar
• Michniak B. B., Player M. R., Godwin D. A., Lockart C. C., Sowell J. W. In vitro evaluation of Azone analogs as dermal penetration enhancers. V. Miscellaneous compounds. Int. J. Pharm. 1998; 161(2)169–178, [CSA]
   Web of Science ®Google Scholar
• Minaskanian G., Peck J. V. Penetration enhancers for transdermal delivery of systemic agents. WO Patent 8802626 A1, April 21,1998
   Google Scholar
• Miniskanian G., Peck J. V. Penetration enhancers for transdermal delivery of systemic agents. US Patent 5,142,044, August 25, 1992
   Google Scholar
• Mirejovsky D., Takrvri H. Dermal penetration enhancement profile of hexamethylene lauramide and its homologues: in vitro versus in vivo behavior of enhancers in the penetration of hydrocortisone. Journal of Pharmaceutical Sciences 1986; 75: 1089–1093, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Monti D., Saettone M. F. Development of a transdermal patch for delivery of propafenone. Preliminary Studies in vitro. S. T. P. Pharma Science 1997; 7(3)235–240, [CSA]
   Web of Science ®Google Scholar
• Morgan T. M., Reed B. I., Finnin B. C. Enhanced skin permeation of sex hormones with novel topical spray vehicles. J. Pharm. Sci. 1998; 87(10)1213–1218, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Naik A., Guy R. H. “Infrared spectroscopic and differential scanning calorimetric investigations of the stratum corneum barrier function. Mechanisms of Transdermal Drug Deliver 1st, R. O. Potts, R. H. Guy, New York: Marcel Dekker 1997; 112–116
   Google Scholar
• Niazy E. M. Differences in penetration-enhancing effect of Azone through excised rabbit, rat, hairless mouse, guinea pig and human skins. Int. J. Pharm. 1996; 130(2)225–230, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Nicolazzo J. A., Reed B. L., Finnin B. C. Modification of buccal drug delivery following pretreatment with skin penetration enhancers. J. Pharm. Sci. 2004; 93(8)2054–2063, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nicolazzo J. A., Reed B. L., Finnin B. C. Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J. Control. Rel. 2005; 105(3)240–248, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Numajiri S., Inada H., Sugibayashi K., Morimoto Y. Iontophoretic transport of morphine across hairless rat skin: Is a further increase obtained with chemical enhancer?. Arch-Pract-Pharm-Yakuzaigaku 1998; 58(1)29–36, [CSA]
   Google Scholar
• Ogiso T., Ito Y., Iwaki M., Atago H., Tanaka C., Maniwa N., Ishida S. Percutaneous absorption of dexamethasone acetate and palmitate, and the plasma concentration. Chemical & Pharmaceutical Bulletin 1987; 35(10)4263–70, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Okamoto H., Hashida M., Sezaki H. Structure-Activity relationship of 1-alkyl- or 1-alkenylazacicloalkanone derivates as percutaneous enhancers. Journal of Pharmaceutical Sciences 1988; 77(5)418–424, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Okamoto H., Hashida M., Sezaki H. Effect of 1-alkyl- or 1-alkenylazacycloalkanone derivates on the penetration of drugs with different lipophilicities trough guinea pig skin. Journal of Pharmacteucil Sciences 1991; 80(1)39–45, [CSA]
   PubMed Web of Science ®Google Scholar
• Peck J. V., Minaskanian G. Transdermal penetration enhancers. US Patent 5,472,946, December 5, 1995
   Google Scholar
• Petersen R. V., Hsu T. M., Lee H. C., Christy D. Percutaneous drug delivery system. US Patent 5,296,222, March 22, 1994
   Google Scholar
• Phillips C. A., Michniak B. B. Transdermal delivery of drugs with differing lipophilicities using Azone analogs as dermal penetration enhancers. J. Pharm. Sci. 1995; 84(12)1427–1433, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ponec M., Haverkort M., Soei L., Kempenaar J. Toxicity screening of n-alkylazacycloheptan-2-one derivatives in cultured human skin cells: structure-toxicity relationships. Journal of Pharmaceutical Sciences 1989; 78(9)738–741, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ponec M., Haverkort M., Soei L., Kempenaar J., Bodde H. Use of human keratinocyte and fibroblast cultures for toxicity studies of topically applied compounds. Journal of Pharmaceutical Sciences 1990; 79(4)312–316, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Potts R. O., Francoeur M. L. Transdermal flux enhancing compositions. EP Patent 331382 A2, September 06, 1989
   Google Scholar
• Puglia C., Bonina F., Trapani G., Franco M., Ricci M. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int. J. Pharm. 2001; 228(1–2)79–87, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacyclopentan-2-ones. US Patent 4,444,762, April 24, 1984b
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacyclohexan-2-ones. US Patent 4,423,040, December 27, 1983c
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacycloalkan-2-ones. US Patent 4,316,893, February 23, 1982
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacycloalkan-2-ones. US Patent 4,424,210, January 3, 1984a
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacyclononan-2-ones. US Patent 4,415,563, November 15, 1983b
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacycloheptan-2-ones. US Patent 3,989,816, November 2, 1976a
   Google Scholar
• Rajadhyaksha V. J. Novel N-bis-azacyclopentan-2-onyl Alkanes. US Patent 3,989,815, (November 2, 1976c)
   Google Scholar
• Rajadhyaksha V. J. Vehicle composition containing 1-substituted azacyclopentan-2-ones. US. Patent 3,991,203, November 9, 1976b
   Google Scholar
• Rajadhyaksha V. J. Physiological vehicle compositions containing higher alkyl substituted azacyclopentan-2-ones. US Patent 4,122,170, October 24, 1978
   Google Scholar
• Rajadhyaksha V. J. Penetration enhancers for transdermal drug delivery of systemic agents. US Patent 4,405,616, September 20, 1983a
   Google Scholar
• Rajadhyaksha V. J., Peck J. V., Miniskanian G. Method of synthesis of 1-dodecylazacycloheptan-2-one. US Patent 4,422,970, December 27, 1983d
   Google Scholar
• Rosendo V. I. Estudio del Efecto de dos Promotores de Absorción (Azona® y 4-Deciloxazolidin-2ona) sobre la Penetración de Fármacos a Través de Mucosa Oral No Queratinizada. Informa UK Ltd, Cuautitlán Izcalli, México 1999; 70
   Google Scholar
• Ruland A., Kreuter J., Rytting J. H. Transdermal delivery of the tetrapeptide hisetal (melanotropin (6–9)). II. Effect of various penetration enhancers. In vitro study across human skin. Int. J. Pharm. 1994a; 103(1)77–80, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Ruland A., Kreuter J., Rytting J. H. Transdermal delivery of the tetrapeptide hisetal [Melanotropin (6–9)]. I. Effect of various penetration enhancers: In vitro study across hairless mouse skin. Int. J. Pharm. 1994b; 101(1–2)57–61, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Samour C. M., Eisenberg S. R. Improved iontophoretic administration of drugs. EP Patent 552879 A1, July 28, 1993
   Google Scholar
• Sato H., Yamaguchi H., Nozawa I., Kusunoki T., Nakajima M. Percutaneously absorbable composition. JP Patent 04334326, A2, November 20, 1992
   Google Scholar
• Schückler F., Lee G. The influence of Azone on monomolecular films of some stratum corneum lipids. International Journal of Pharmaceutics 1991; 70: 173–186, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Schückler F., Bouwstra J. A., Gooris G. S., Lee G. An x-ray diffraction study of some model stratum corneum lipids containing Azone and dodecyl-L-pyroglutamate. Journal of Controlled Release 1993; 23(1)27–36, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Sekine T., Machida Y., Nagai T. Gel ointment of verapamil for percutaneous absorption. Drug Des. Deliv. 1987; 1(3)245–52, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Singh B. N., Singh R. B., Singh J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum Int. J. Pharm. 2005; 298(1)98–107, [CSA]
   Google Scholar
• Smith J. C., Irwin W. J. Ionization and the effect of absorption enhancers on transport of salicylic acid through silastic rubber and human skin. Int. J. Pharm. 2000; 210(1–2)69–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Squillante E., Maniar A., Needham T., Zia H. Optimization of in vitro nifedipine penetration enhancement through hairless mouse skin. Int. J. Pharm. 1998; 169(2)143–154, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Tenjarla S. N., Kasina R., Puranajoti P., Omar M. S., Harris W. T. Synthesis and Evaluation of N-Acetylprolinate Esters—Novel Skin Penetration Enhancers. Int. J. Pharm. 1999; 192(2)147–158, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tenjarla S., Puranajoti P., Kasina R., Mandal T. Terbutaline transdermal delivery: Preformulation studies and limitations of in vitro predictive parameters. J. Pharm. Pharmacol. 1996; 48(11)1138–1142, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Turnen T. M., Urtti A., Paronen P., Audus K. L., Rytting J. H. Effect of some penetration enhancers on epithelial membrane lipid domains: Evidence from fluorescence spectroscopy studies. Pharm. Res. 1994; 11(2)288–314, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Vávrová K., Hrabálek A., Dol˛eal P., Holas T., Klimentová J. Biodegradable derivatives of tranexamic acid as transdermal permeation enhancers. J. Control. Rel. 2005; 104(1)410–49, [CSA]
   Web of Science ®Google Scholar
• Vaidyanathan R., Vo P. M., Manning G. N., Gerhart D. J., Allan G., Helmy A. A. Topical pharmaceutical formulations comprising skin penetration agents. WO Patent 0100139 A1, January 04, 2001
   Google Scholar
• Wiechers J. W. Metabolism of the penetration enhacer azone®: In Vivo and In Vitro Studies in Hamster, Rat, Monkey and Human. Percutaneous Penetration Enhancers, E. W. Smith, H. I. Maibach. Informa UK Ltd, New York 1995; 165–181
   Google Scholar
• Wiechers J. W., Zeeuw R. A. Transdermal drug delivery: efficacy and potential applications of the penetration enhancer Azone®. Drug Design and Delivery, M. Honan. Informa UK Ltd, London 1990a, 6, chap. 5
   Google Scholar
• Wiechers J. W., Drenth B. F., Jonkman J. H. Percutaneous absorption, metabolic profiling, and excretion of the penetration enhancer azone after multiple dosing of an azone-containing triamcinolone acetonide cream in humans. Journal of Pharmaceutical Sciences 1990b; 79(2)111–115, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wiechers J. W., Drenth B. F., Jonkman J. H., De Zeeuw R. A. Percutaneous absorption of triamcinolone acetonide from creams with and without Azone in humans in vivo. International Journal of Pharmaceutics 1990c; 66(1–3)53–62, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Wiechers J. W., Drenth, Ben F. H., Jonkman, Jan H. G., De Zeeuw R.A. Percutaneous absorption and elimination of the penetration enhancer Azone in humans. Pharm. Res. 1987; 4(6)519–523, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Williams A., Barry B. W. Penetration enhancers. Advanced Drug Delivery Reviews 2004; 56: 603–618, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Xie X. Controlled-release diclofenac sodium patches. CN Patent 1174031 A, February 25, 1998
   Google Scholar
• Xing G., Miao C., Zhao L. Effects of penetration enhancers on permeation of indomethacin from ointment. Zhongguo Yiyuan Yaoxue Zazhi 2000; 20(11)662–664, [CSA]
   Google Scholar
• Xu Z. Y., Huang S. J., Ruan L. J. Transdermal absorption of galanthamine hydrobromide through mice skin in vitro. Yaoxue Fuwu Yu Yanjiu 2002; 2(2)88–91, [CSA]
   Google Scholar
• Yang D., Yang Y., Wang Y., Dong S. New drug form for human body cavity and its implementation. CN Patent 1297778 A, June 6, 2001
   Google Scholar
• Yang T., Yi Y. Effect of mixed transdermal enhancers on percutaneous absorption of aspirin gel. Tongji Yike Daxue Xuebao 2001; 30(6)533–534, [CSA]
   Google Scholar
• Yu J., Cheng Y., Song Y. Effects of pH and Azone on transdermal absorption of chrysophanic acid. Zhongcaoyao 1999; 30(5)358–360, [CSA]
   Google Scholar
• Zaprutko L., Partyka D., Bednarczyk-Cwnar B. Triterpenoids. Part 21: Oleanolic Acid Azaderivatives as percutaneous transport promoters. Bioorganic & Medicinal Chemistry Letters 2004; 14: 4723–4726, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar